Microbicides for prevention of HIV infection: clinical efficacy trials.

HIV Infection and AIDS in Sub-Saharan Africa: Current Status, Challenges and Opportunities. Open AIDS J (2016) 0.94

Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment. J Control Release (2015) 0.83

Abolishing HIV-1 infectivity using a polypurine tract-specific G-quadruplex-forming oligonucleotide. BMC Infect Dis (2016) 0.75

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (2010) 35.19

Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med (2010) 10.90

Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med (2011) 5.31

Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection. N Engl J Med (2015) 3.64

Symptomatic vaginal discharge is a poor predictor of sexually transmitted infections and genital tract inflammation in high-risk women in South Africa. J Infect Dis (2012) 2.42

Microbicides & their implications in HIV prevention. Indian J Med Res (2010) 2.36

Preventing HIV infection in women: a global health imperative. Clin Infect Dis (2010) 1.47

The relationship between obesity and complications after neonatal circumcision. J Urol (2011) 1.39

Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials (2011) 1.15

Contraceptive choices, pregnancy rates, and outcomes in a microbicide trial. Obstet Gynecol (2011) 1.13

Utilizing nucleic acid amplification to identify acute HIV infection. AIDS (2007) 1.07

Global epidemiology of HIV-AIDS. Infect Dis Clin North Am (2007) 1.06

Adherence in the CAPRISA 004 tenofovir gel microbicide trial. AIDS Behav (2014) 1.06

When to start antiretroviral therapy during tuberculosis treatment? Curr Opin Infect Dis (2013) 0.94

Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial. Antivir Ther (2012) 0.94

Topical microbicides--what's new? J Acquir Immune Defic Syndr (2013) 0.92

Antiretroviral therapy: challenges and options in South Africa. Lancet (2003) 0.91

Overview of microbicides for the prevention of human immunodeficiency virus. Best Pract Res Clin Obstet Gynaecol (2012) 0.90

Prevention of HIV in Adolescent Girls and Young Women: Key to an AIDS-Free Generation. J Acquir Immune Defic Syndr (2017) 0.89

The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis. S Afr Med J (2010) 0.85

Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial. Trials (2014) 0.83

A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection. Expert Opin Investig Drugs (2012) 0.82

Microbicides for the prevention of sexually transmitted HIV infection. Expert Rev Anti Infect Ther (2013) 0.78

Antibodies for HIV prevention in young women. Curr Opin HIV AIDS (2015) 0.77